The US Food and Drug Administration (FDA) approval in December 2023, of two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of a rare disease called sickle cell disease (SCD) in patients 12 years and older, is a huge development. With rare diseases posing significant challenges due to the scarcity of information, limited research, and insufficient awareness among healthcare professionals and the public, introduction and approval of s...
New Clinical AI care suites for Cardiology, Pulmonology, and Neurology; First-in-Class multi-modal predictive and Gen AI platform for research and clinical model development....
Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024....
Avanos Medical, Inc. Initiates Voluntary Recall Following Nurse Assist, LLC's Sterile Water Medical Products Recall...
First-ever installation in Fortis Hospital, Bengaluru...
Introducing RetinAI Discovery® Platform and AI Tools for Enhanced Clinical Decision Making and Patient Management...
Equipped with a 2D Fan Beam, the machine provides the highest image resolution for a precise diagnosis...
This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S....
Jiva.ai and Aevice Health collaborate to pioneer breakthrough medical AI for asthma adverse event prediction based on Aevice Health’s FDA-cleared remote patient monitor....
CARDIOVIT® FT-2 is SCHILLER’s answer to the highest hospital demands. We are proud to announce our brand-new hospital ECG device CARDIOVIT® FT-2. ...
